Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.2552W HIGH $9.32
Volume
637.04 K
Value Traded
1.82 M
Short % Float
14.17%
+4.56%Week
-6.31%1 Month
+13.32%3 Month
+10.35%6 Month
+154.57%5 Year
+154.57%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
492.19 M
EPS (TTM)
-1.01
P/E Ratio
-
Ent. Value
327.58 M
Total Shares
65.02 M
Float Shares
53.52 M
Insiders
18.79%
Institutions
40.41%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
EPRX Catalyst Timeline
Dated clinical, regulatory and corporate events for Eupraxia Pharmaceuticals Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Eupraxia Pharmaceuticals Inc.
161Total events
11Upcoming
45Tier-1 (high impact)
2023 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Safety Data UpdateEP-104GIClinical Data
EP-104GI safety and tolerability data reported to date in RESOLVE Phase 1b/2a
Eosinophilic Esophagitissource ↗
▲Long Term DataEP-104GIClinical Data
EP-104GI 52-week durability data from Cohort 9 of RESOLVE Phase 1b/2a
Eosinophilic Esophagitissource ↗
●Timing GuidancePresentation
Eupraxia management to present at Cantor Global Healthcare Conference
▲Additional DataEP-104GIClinical Data
Positive symptom response data from RESOLVE trial including odynophagia analysis
Eosinophilic Esophagitissource ↗
▲Oral PresentationEP-104GIPresentation
Data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI
▲Management ChangeCorporate
Strengthened executive team and board to bolster late-stage drug development and global commercialization capabilities
▲Quarterly UpdateCorporate
Appointment of Robert Bazemore, Amy Pott, and Dr. Helen Thackray to Board of Directors
◆Topline ReadoutEP-104GIClinical Data
Top-line data from Phase 2b part of RESOLVE trial expected
eosinophilic esophagitissource ↗
◆Oral PresentationPresentation
Eupraxia management to present at Jefferies Global Healthcare Conference
▲Oral PresentationEP-104GIPresentation
First release of EoEHSS sub scores data at Digestive Disease Week
eosinophilic esophagitissource ↗
◆Poster PresentationEP-104GIPresentation
Poster presentation of EP-104GI data from RESOLVE trial at DDW 2026
eosinophilic esophagitissource ↗
▲Oral PresentationEP-104GIPresentation
EREFS data presented at DDW 2026
eosinophilic esophagitissource ↗
◆R&D DayEP-104GIPresentation
Virtual investor event at DDW 2026 featuring KOLs and EP-104GI discussion
eosinophilic esophagitissource ↗
◆Oral PresentationEP-104GIPresentation
Oral presentation of EP-104GI data from RESOLVE trial at DDW 2026
eosinophilic esophagitissource ↗
◆Oral PresentationPresentation
Presentation at 2026 Bloom Burton & Co. Healthcare Investor Conference
▲Full ResultsEP-104GIClinical Data
36-week tissue health and symptom data from highest dose cohort (Cohort 9) reported
eosinophilic esophagitissource ↗
◆Enrollment UpdateEP-104GITrial
Phase 2b part of RESOLVE trial currently recruiting
eosinophilic esophagitissource ↗
◆Topline ReadoutEP-104GIClinical Data
Topline data from Phase 2b portion of RESOLVE trial expected
Eosinophilic Esophagitissource ↗
▲Topline ReadoutEP-104GIClinical Data
Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI
Eosinophilic Esophagitissource ↗
▲Full ResultsEP-104GIClinical Data
Reported 24-week symptom data from highest dose cohort (Cohort 9) in Phase 1b/2a RESOLVE trial
eosinophilic esophagitissource ↗
▼Equity OfferingCorporate
Closing of US$63.2 million public offering including full exercise of underwriter option
▼Equity OfferingCorporate
Pricing of US$55 million public offering of common shares and pre-funded warrants
▲Topline ReadoutEP-104GIClinical Data
Positive 12-week and 36-week tissue health data from Phase 1b/2a part of RESOLVE trial
eosinophilic esophagitissource ↗
●Enrollment UpdateEP-104GITrial
Phase 2b part of RESOLVE trial currently recruiting
eosinophilic esophagitissource ↗
▲Full ResultsEP-104GIClinical Data
52-week follow-up data from Cohort 6 of RESOLVE trial
eosinophilic esophagitissource ↗
◆Additional DataEP-104GIClinical Data
Additional data from open-label Phase 1b/2a part to be disclosed
eosinophilic esophagitissource ↗
▲First Patient DosedEP-104GITrial
First patient dosed in Phase 2b part of RESOLVE trial
eosinophilic esophagitissource ↗
▲Oral PresentationEP-104GIPresentation
Late-breaking presentation at ACG Annual Scientific Meeting
eosinophilic esophagitissource ↗
◆Additional DataEP-104GIClinical Data
Additional data from open-label Phase 1b/2a part of RESOLVE trial expected in Q4 2025
Eosinophilic Esophagitissource ↗
◆Full ResultsEP-104GIClinical Data
Additional data from cohorts 5-8 of Phase 1b/2a RESOLVE trial
Eosinophilic Esophagitissource ↗
▲Topline ReadoutEP-104GIClinical Data
Positive data from highest-dose cohort (8mg per injection) in RESOLVE trial
Eosinophilic Esophagitissource ↗
●Enrollment UpdateEP-104GITrial
Phase 2b RESOLVE trial currently recruiting patients
Eosinophilic Esophagitissource ↗
▼Equity OfferingCorporate
Closing of US$80.5 million public offering including full exercise of underwriter option
▲Runway Guidance UpdateCorporate
Company believes it is now capitalized into first quarter of 2028
▼Equity OfferingCorporate
Pricing of US$70 million public offering of common shares at US$5.50 per share
▲Full ResultsEP-104GIClinical Data
Positive 52-week data from Phase 1b/2a RESOLVE Trial showing durable symptom and tissue responses
eosinophilic esophagitissource ↗
Past FDA Catalysts and PDUFA Decisions
How EPRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | EP-104GI | Phase 2b topline data readout | Phase 2b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D35 / 100
Pipeline Score
$93M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.2x
rNPV / MCap
Top 54%
Micro Cap(rank 356 of 658)
Percentile Rank
Eupraxia Pharmaceuticals Inc. faces pipeline headwinds (35/100), with $379M risk-adjusted pipeline value, led by EP-104IAR in Osteoarthritis, Knee (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EP-104IAR Small moleculeCompletedNCT02609126 | Osteoarthritis, Knee | Phase 2 | COMPLETED | 350 | Dec 28, 2017 |
Clinical Trial Results
Readouts, endpoints and source filings for every EPRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| EP-104GI | Eosinophilic Esophagitis | Phase 1b/2a | 2026-09-30 | 66% of patients in the highest dose cohort maintained clinical remission; 9 of 14 patients (64%) have remained in clinical remission 52 weeks after receiving a single administration of EP-104GI; mean reduction in SDI at 36 weeks was 3.3 in Cohort 8b; mean reduction in SDI at 36 and 52 weeks was 3.0 in Cohort 9; 53% (10/19) of patients achieved clinical remission at 12 weeks; 78% (14/18) of patients maintained clinical remission at 24 weeks; 61% (11/18) of patients maintained clinical remission at 36 weeks; 64% (9/14) of patients maintained clinical remission at 52 weeksRead More | Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic EsophagitisRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in EPRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| AFFINITY ASSET ADVISORS, LLC | 0.5 % (-16.7 %) | 10.91 M | 1.65 M | 3.84% ( 60.99 K) |
EPRX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EPRX ranks across every disease it competes in
Competitive Position is a premium feature
See how EPRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEPRX News
EPRX▲ +9.6%on this news
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals has reported positive 52-week data from its Phase 1b/2a RESOLVE trial for EP-104GI, showing that 66% of patients in the highest dose cohort maintained clinical remission. The trial also indicated meaningful histologic improvements in inflammation and fibrosis. The treatment was well tolerated, with no serious adverse events reported, suggesting a promising future for EP-104GI in treating Eosinophilic Esophagitis.
Read more →EPRXEupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences
Eupraxia Pharmaceuticals has announced its common shares are now trading on the Nasdaq Global Select Market, marking a significant milestone for the company. This transition reflects Eupraxia's adherence to stringent financial and governance standards. Additionally, the management team will participate in several investor conferences in New York, showcasing their ongoing clinical programs and commitment to creating value.
Read more →EPRXEupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
Eupraxia Pharmaceuticals reported positive results from its Phase 1b/2a RESOLVE trial, indicating that EP-104GI significantly reduces symptoms of odynophagia and dysphagia in eosinophilic esophagitis (EoE) patients. The trial showed no serious adverse events, and patients experienced improvements lasting up to 52 weeks. The company anticipates further data from the Phase 2b trial later this year.
Read more →EPRXEupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
Eupraxia Pharmaceuticals reported positive financial results for Q2 2026, highlighting new data from Digestive Disease Week (DDW) that shows significant improvements in fibrosis and inflammation after a single treatment with EP-104GI. The company has also strengthened its executive team and board to enhance its capabilities in late-stage drug development and global commercialization.
Read more →EPRXEupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth
Eupraxia Pharmaceuticals has strengthened its executive leadership team with the appointment of Dr. Jeff Millard as Executive Vice President of Technical Operations and Dr. Alex Therien as Executive Vice President of Research & Development. This restructuring aims to support the company's growth as it prepares for the Phase 3 development of its product EP-104GI, following positive results from the Phase 2a RESOLVE trial. The company is also transitioning to a two-hub organization to enhance its clinical operations.
Read more →EPRXEupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization
Eupraxia Pharmaceuticals has appointed three industry leaders, Robert Bazemore, Amy Pott, and Dr. Helen Thackray, to its Board of Directors. This move aims to enhance the company's capabilities in drug development and commercialization, particularly for its gastroenterology assets. The appointments come at a crucial time as Eupraxia looks to advance its pipeline and achieve key milestones.
Read more →EPRXEupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders
Eupraxia Pharmaceuticals announced the successful results of its Annual General Meeting held on June 18, 2026. All seven board nominees proposed by management were elected, and KPMG LLP was re-appointed as the company's auditor. The meeting's outcomes reflect shareholder confidence in the company's direction and governance.
Read more →EPRXEUPRAXIA PHARMACEUTICALS INC.
Eupraxia Pharmaceuticals Inc. will hold its Annual General Meeting on June 18, 2026, in a virtual-only format. Shareholders are encouraged to participate via live webcast, where they can ask questions and vote online. The notice includes guidelines on proxy voting and the process for attending the meeting. Registered shareholders must take note of the voting process outlined in the Management Information Circular to ensure their participation.
Read more →EPRXEupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Eupraxia Pharmaceuticals will present at the Jefferies Global Healthcare Conference on June 3, 2026. The company focuses on innovative drug delivery systems using its Diffusphere™ technology. Currently, Eupraxia is advancing its clinical trials, including EP-104GI for EoE and EP-104IAR for knee osteoarthritis pain, which has shown positive results in earlier trials.
Read more →EPRXEupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
Eupraxia Pharmaceuticals reported strong financial results for Q1 2026, highlighting a robust response from the highest dose cohort of EP-104GI in its clinical trials. The company successfully completed a $63.2 million public offering, ensuring funding for ongoing and future clinical programs. Despite a net loss increase, Eupraxia remains well-capitalized into 2028, with over $140 million in cash.
Read more →EPRXEUPRAXIA PHARMACEUTICALS INC. CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2026 (Unaudited and Expressed in U.S. Dollars)
Eupraxia Pharmaceuticals Inc. announced its consolidated financial results for the three-month period ending March 31, 2026. The company experienced a net loss of $12.65 million, which is an increase from the $6.77 million loss reported in the same period of the previous year. Their total assets rose significantly, but the company's total liabilities and consolidated deficit also increased, raising concerns about their financial stability. The balance sheet reflects an ongoing trend of increasing losses alongside a reduction in cash reserves.
Read more →EPRXEupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
Eupraxia Pharmaceuticals has released promising sub score data from its ongoing Phase 1b/2a RESOLVE trial for EP-104GI, aimed at treating eosinophilic esophagitis (EoE). The data, presented at Digestive Disease Week, indicates significant improvements in both inflammation and fibrosis in patients. The highest dose cohorts showed the most substantial benefits, suggesting potential for effective treatment in EoE patients.
Read more →EPRXEupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)
Eupraxia Pharmaceuticals presented promising EREFS data from its ongoing Phase 1b/2a RESOLVE trial for EP-104GI in eosinophilic esophagitis at the Digestive Disease Week conference. The data demonstrated a strong correlation between the number of injections and improvements in esophageal inflammation and fibrosis. Notably, patients receiving 20 injections showed a significant reduction in EREFS scores, indicating potential efficacy of the treatment.
Read more →EPRXEupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
Eupraxia Pharmaceuticals has appointed Dr. Jeymi Tambiah as Chief Medical Officer, succeeding Dr. Mark Kowalski. Dr. Tambiah brings over 18 years of experience in clinical development and regulatory strategy. His appointment comes at a crucial time as the company advances its EP-104GI program for Eosinophilic Esophagitis, aiming to expand its gastroenterology pipeline.
Read more →EPRXEupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
Eupraxia Pharmaceuticals announced its participation in the Digestive Disease Week Annual Meeting, where it will present four abstracts related to its EP-104GI treatment for eosinophilic esophagitis. The presentations will highlight findings from the Phase 1b/2 RESOLVE trial, showcasing improvements in histological features and inflammation. Additionally, the company will host a virtual investor event featuring key opinion leaders discussing esophageal strictures.
Read more →EPRXEupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
Eupraxia Pharmaceuticals has reported promising results from the highest dose cohort of its Phase 1b/2a RESOLVE trial for EP-104GI in treating eosinophilic esophagitis. At 36 weeks, patients showed significant improvements in tissue health and symptom relief, with 66% maintaining clinical remission. The treatment was well tolerated, with no serious adverse events noted.
Read more →EPRXEupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
Eupraxia Pharmaceuticals Inc. will present at two upcoming investor conferences, including the Raymond James Biotech Innovation Symposium and the Bloom Burton & Co. Healthcare Investor Conference. The company is focused on its proprietary Diffusphere™ technology for optimized drug delivery, with ongoing clinical trials for treatments targeting eosinophilic esophagitis and knee osteoarthritis. Eupraxia aims to address significant unmet medical needs across various therapeutic areas.
Read more →EPRXEupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
Eupraxia Pharmaceuticals has reported encouraging 24-week symptom data from its Phase 1b/2a RESOLVE trial for EP-104GI, targeting eosinophilic esophagitis. Patients in the highest dose cohort experienced a notable average reduction in symptom scores, with a significant percentage achieving clinical remission. The treatment was well tolerated, with no serious adverse events recorded, highlighting its potential as a new therapeutic option.
Read more →EPRXEupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
Eupraxia Pharmaceuticals reported its financial results for Q4 2025, highlighting a net loss of $16.7 million, up from $7.5 million in the previous year. The company achieved significant clinical milestones and anticipates multiple readouts from its ongoing RESOLVE trial. With a strengthened balance sheet, Eupraxia is positioned for growth and plans to expand its clinical programs.
Read more →EPRXEupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
Eupraxia Pharmaceuticals Inc. announced the closure of a public offering that raised approximately US$63.2 million. The funds from this offering will primarily be used to advance the company's EP-104GI for eosinophilic esophagitis and to expand its pipeline into other gastrointestinal indications. The offering included 7,607,145 common shares sold at US$7.00 each, along with additional pre-funded warrants. The company aims to achieve commercial readiness and reach several development milestones with the proceeds.
Read more →About Eupraxia Pharmaceuticals Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next EPRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime